Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group
09 juin 2022 08h00 HE
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences to Present at the BIO International Convention 2022
08 juin 2022 08h00 HE
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
26 mai 2022 08h00 HE
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J. and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to...
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
23 mai 2022 16h05 HE
|
Caladrius Biosciences, Inc.
Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022...
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
19 mai 2022 08h00 HE
|
Caladrius Biosciences, Inc.
Independent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns observed in the first two patients dosed Top-line data from all subjects...
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
18 mai 2022 08h00 HE
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
05 mai 2022 16h05 HE
|
Caladrius Biosciences, Inc.
Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial position while advancing and expanding development...
Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time
28 avr. 2022 08h00 HE
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement
27 avr. 2022 07h00 HE
|
Caladrius Biosciences, Inc.
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong...
Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease
12 avr. 2022 08h00 HE
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...